CABA
Cabaletta Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.43
−1.42%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 157.8M | 142.7M | 97.2M | 55.4M | 39.3M |
| SG&A Expense | 27.7M | 29.6M | 27.9M | 19.2M | 14.8M |
| General & Admin Expense | 27.7M | 29.6M | 27.9M | 19.2M | 14.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 185.5M | 172.2M | 125.1M | 74.7M | 54.1M |
| Cost and Expenses | 185.5M | 172.2M | 125.1M | 74.7M | 54.1M |
| Operating Income (EBIT) | (185.5M) | (172.2M) | (125.1M) | (74.7M) | (54.1M) |
| Non-Operating | |||||
| Interest Income | 5.8M | 6.0M | 10.0M | 7.0M | 1.2M |
| Interest Expense | 2.3M | 2.0M | 748.0K | — | — |
| Net Interest Income | 3.5M | 4.0M | 9.3M | 7.0M | 1.2M |
| Other Non-Op Income/Expense | 4.2M | 4.4M | 9.3M | 7.0M | 1.2M |
| Non-Operating Income (excl Interest) | (6.5M) | (6.4M) | (10.0M) | (7.0M) | (1.2M) |
| EBT (Pre-Tax Income) | (181.3M) | (167.9M) | (115.9M) | (67.7M) | (53.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (181.3M) | (167.9M) | (115.9M) | (67.7M) | (53.0M) |
| Earnings from Cont. Ops | (181.3M) | (167.9M) | (115.9M) | (67.7M) | (53.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (181.3M) | (167.9M) | (117.0M) | (67.7M) | (53.0M) |
| Per Share | |||||
| Basic EPS | ($1.58) | ($1.64) | ($2.34) | ($1.65) | ($1.81) |
| Diluted EPS | ($1.58) | ($1.64) | ($2.34) | ($1.65) | ($1.81) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 151.2M | 102.3M | 49.5M | 40.9M | 29.3M |
| Diluted Shares Outstanding | 151.2M | 102.3M | 49.5M | 40.9M | 29.3M |
| Profitability Metrics | |||||
| EBITDA | (176.9M) | (164.2M) | (113.4M) | (66.2M) | (51.8M) |
| D&A | 2.1M | 1.6M | 1.7M | 1.4M | 1.2M |
| EBIT | (179.0M) | (165.9M) | (115.1M) | (67.7M) | (53.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026